Four pan-HDAC inhibitors [Vorinostat (SAHA), Belinostat (PXD-101), Romidepsin (FK-228) and Panobinostat (LBH589)] have received FDA approvals, primarily for the treatment of hematological malignancies. Here, HDAC9 is linked to hematologic disorder.